AllSci News
4Moving Biotech’s 4P004 GLP-1 analog gains FDA Fast Track status for knee osteoarthritis
4Moving Biotech, a clinical-stage biotechnology company headquartered at the Pasteur Institute in Lille, France, announced receipt of US FDA Fast Track Designation…
BioAegis and Prenosis collaborate to identify ARDS biomarkers using AI-driven precision medicine analytics
BioAegis Therapeutics, a private clinical-stage company based in North Brunswick, N.J., has announced a collaboration with Prenosis to apply AI-driven analytics to…
Ractigen posts early RAG-17 ALS data with strong biomarker signals but limited patient numbers
Ractigen Therapeutics reported Phase I data from its RAG-17 program in SOD1-ALS showing an 81.2% reduction in plasma neurofilament light chain from a single...
FDA approves Merck’s Idvynso for HIV-1 treatment in virologically suppressed adults
The US FDA approved Idvynso (doravirine/islatravir) for Merck, marking the first non-integrase strand transfer inhibitor (INSTI), tenofovir-free, once-daily complete two-drug regimen to…
Roche’s BTK inhibitor fenebrutinib posts Phase III MS win, overshadowed by deaths imbalance
Roche (SWX: RO; OTCQX: RHHBY) reported that fenebrutinib cut annualized relapse rates by 51.1% and 58.5% versus teriflunomide across two Phase III trials in...
NEJM case report documents first ADC-induced hepatic pseudoprogression using Mabwell's Nectin-4 ADC in cervical cancer
Second People's Hospital of Yibin researchers report hepatic pseudoprogression following Nectin-4 ADC treatment in cervical cancer in NEJM
FDA approves new indication for Sanofi’s Tzield to delay type 1 diabetes onset in children
Sanofi received US FDA approval for an expanded indication for Tzield (teplizumab-mzwv), extending the drug’s use to children as young as one…
Regeneron's cemdisiran meets primary endpoints in Phase III generalized myasthenia gravis trial
Regeneron Pharmaceuticals (Nasdaq: REGN) reported that cemdisiran, its investigational siRNA therapeutic, met both the primary and key secondary endpoints...
Eli Lilly fully backs out of USD 960m ocadusertib collaboration with Rigel
Eli Lilly and Company (NYSE: LLY) has notified Rigel Pharmaceuticals (NASDAQ: RIGL) of its election to terminate a License and Collaboration Agreement...
Renaissance Pharma's daretabart receives FDA Fast Track designation for high-risk neuroblastoma
Renaissance Pharma Limited announced in April 2026 that the US FDA had granted Fast Track Designation for daretabart (hu1418K322A) and cleared the company's...
Lytix Bio's oncolytic peptide ruxotemitide shows benefit in checkpoint inhibitor-refractory melanoma
Lytix Biopharma reported final Phase II data for ruxotemitide (LTX-315) combined with pembrolizumab in checkpoint inhibitor-refractory advanced melanoma,...
Ray Therapeutics raises USD 125m Series B for optogenetic gene therapy programs
Ray Therapeutics, a Berkeley, California-based clinical-stage biopharmaceutical company developing optogenetic gene therapies for retinal degenerative...
Merck and Eisai's triplet and MK-1308A regimens fall short against Keytruda combo in RCC Phase III
Merck (NYSE: MRK) and Eisai reported that neither experimental combination regimen tested in the Phase III LITESPARK-012 trial met the dual primary...
Flagship launches Serif Biomedicines with USD 50m to advance modified DNA therapeutics
Flagship Pioneering launched Serif Biomedicines with an initial USD 50 million commitment to develop a new class of modified DNA-based medicines, the…
AstraZeneca's ravulizumab aces endpoint in Phase III immunoglobulin A nephropathy trial
AstraZeneca's Alexion unit reported that ravulizumab (Ultomiris) met the proteinuria primary endpoint in a prespecified interim analysis of the Phase III I...
The AllSci Brief
Systematic R&D and deal news. Daily.